Philippe JEAN-PIERRE

---

• Type de publi. : Article dans une revue
• Date de publi. : 07/08/2024
• Auteurs : Bénédicte CaronPhilippe SeksikA. BuissonPauline WilsGuillaume SavoyeCarmen StefanescuDavid LaharieLucas GuilloVered AbitbolJoelle BonnetRomain AltweggLucine VuittonDriffa MoussataArnaud BourreilleAmélie BironCyrielle GillettaMathurin FumeryStephane NahonStéphane NanceyHouda CamaraLaurent Peyrin‐Biroulet
• Organismes : Nutrition-Génétique et Exposition aux Risques Environnementaux Centre Hospitalier Régional Universitaire de Nancy CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine Service Hépato-Gastro-Entérologie [CHU Clermont-Ferrand] Microbes, Intestin, Inflammation et Susceptibilité de l'Hôte Institute for Translational Research in Inflammation - U 1286 Centre Hospitalier Régional Universitaire [CHU Lille] Nutrition, Inflammation et axe Microbiote-Intestin-Cerveau Université de Rouen Normandie Service d'Hépato-Gastroentérologie [CHU Rouen] Clinique Ambroise Paré [Centres Médico-Chirurgicaux Ambroise Paré, Pierre Cherest, Hartmann] Hôpital Beaujon [AP-HP] Centre Hospitalier Universitaire de Bordeaux Hôpital Haut-Lévêque [CHU Bordeaux] CIC Bordeaux CHU Marseille Aix Marseille Université Hôpital Cochin [AP-HP] Hopital Saint-Louis [AP-HP] Département d'Hépato-Gastroentérologie et de Transplantation Hépatique [CHU Saint-Eloi] Centre Hospitalier Régional Universitaire de Besançon Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) Centre Hospitalier Régional Universitaire de Tours Centre Hospitalier Universitaire de Nantes = Nantes University Hospital Centre d’Investigation Clinique de Nantes Hôpital universitaire Robert Debré [Reims] Service Gastroentérologie, hépatologie nutrition, diabétologie et maladies héréditaires du métabolisme pédiatrique [CHU Toulouse] Service d'Hépato Gastroenterologie [CHU Amiens-Picardie] Université de Picardie Jules Verne Groupe Hospitalier Intercommunal Le Raincy-Montfermeil Centre International de Recherche en Infectiologie Centre Hospitalier Lyon Sud [CHU - HCL] Autophagie infection et immunité - Autophagy Infection Immunity [CIRI] Centre Hospitalier Régional Universitaire de Nancy Centre Hospitalier Régional Universitaire de Nancy Nutrition-Génétique et Exposition aux Risques Environnementaux Research Institute of the McGill University Health Centre
• Publié dans Therapeutic Advances in Gastroenterology le 28/10/2020

---

Résumé : Background: Several adalimumab preparations are now available for patients with inflammatory bowel disease (IBD). Comparative satisfaction and tolerability are unknown. Objectives: This study investigated IBD patient satisfaction with approved adalimumab biosimilars and their originator. Design: In this cross-sectional study, we included 941 consecutive adalimumab-treated patients with IBD across 45 centres affiliated with the Groupe d’Etude Therapeutique des Affections Inflammatoires du tube Digestif who completed a satisfaction questionnaire comprising four items each rated by a 10-point scale. Methods: The differences in responses were performed using a one-way analysis of variance followed by Tukey’s honest significant difference test. Results: The most commonly used drugs at inclusion were Humira ® (436/941, 46.3%), Amgevita ® (177/941, 18.8%) and Hulio ® (105/941, 11.2%). The mean overall satisfaction rate with adalimumab was 8.5 (standard deviation 1.8). Overall satisfaction was significantly higher in patients treated with Humira (8.6 (1.5)), Hulio (8.6 (1.8)) or Amgevita (8.5 (1.4)) ( p < 0.05). Satisfaction with the subcutaneous injection form was higher for patients treated with Yuflyma ® (9.0 (1.4)), Humira (8.9 (1.3)) and Hulio (8.9 (1.7)) ( p < 0.05). A total of 299 patients (31.8%) described injection site reactions. In all, 223 patients (23.7%) reported being previously treated with another adalimumab of which (32/223, 14.3%) discontinued treatment due to side effects. Conclusion: In this real-world setting, patients with IBD had a high level of satisfaction with adalimumab treatment, with some differences in terms of overall satisfaction and satisfaction with the injection device.

---

Fichiers liés : caron-et-al-2024-patient-preferences-for-adalimumab-in-inflammatory-bowel-disease-a-nationwide-study-from-the-getaid.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 06/08/2024
• Auteurs : Vincent JonchèreHugo MontémontEnora Le ScanfAurélie SiretQuentin LetourneurEmmanuel TubacherChristophe BattailAssane FallKarim LabrecheVictor RenaultToky RatovomananaOlivier BuhardAriane JollyPhilippe Le RouzicCody FeysEmmanuelle DesprasHabib ZoualiRémy NicollePascale CerveraMagali SvrcekPierre BourgoinHélène BlanchéAnne BolandJérémie LefèvreYann ParcMehdi TouatFranck BielleDanielle ArzurGwennina CueffCatherine Le Jossic-CorcosGaël QuéréGwendal DujardinMarc BlondelCédric Le MaréchalRomain CohenThierry AndréFlorence CouletPierre de la GrangeAurélien de ReynièsJean-François FléjouFlorence RenaudAgusti AlentornLaurent CorcosJean-François DeleuzeAda ColluraAlex Duval
• Organismes : Site de recherche intégrée en cancérologie Centre de Recherche Saint-Antoine Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Centre National de Recherche en Génomique Humaine Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie GenoSplice [Paris] Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Ligue Nationale Contre le Cancer - Paris Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Centre National de Recherche en Génomique Humaine Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie Institut du Cerveau = Paris Brain Institute Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Site de recherche intégrée en cancérologie Sorbonne Université Site de recherche intégrée en cancérologie Sorbonne Université Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université GenoSplice [Paris] Ligue Nationale Contre le Cancer - Paris Site de recherche intégrée en cancérologie AP-HP. Sorbonne Université Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie Génétique, génomique fonctionnelle et biotechnologies (UMR 1078) Centre National de Recherche en Génomique Humaine Fondation Jean Dausset - Centre d’Études du Polymorphisme Humain Site de recherche intégrée en cancérologie Site de recherche intégrée en cancérologie
• Publié dans Genome Biology le 25/10/2020

---

Résumé : Background: Microsatellite instability (MSI) due to mismatch repair deficiency (dMMR) is common in colorectal cancer (CRC). These cancers are associated with somatic coding events, but the noncoding pathophysiological impact of this genomic instability is yet poorly understood. Here, we perform an analysis of coding and noncoding MSI events at the different steps of colorectal tumorigenesis using whole exome sequencing and search for associated splicing events via RNA sequencing at the bulk-tumor and single-cell levels.

Results: Our results demonstrate that MSI leads to hundreds of noncoding DNA mutations, notably at polypyrimidine U2AF RNA-binding sites which are endowed with cis-activity in splicing, while higher frequency of exon skipping events are observed in the mRNAs of MSI compared to non-MSI CRC. At the DNA level, these noncoding MSI mutations occur very early prior to cell transformation in the dMMR colonic crypt, accounting for only a fraction of the exon skipping in MSI CRC. At the RNA level, the aberrant exon skipping signature is likely to impair colonic cell differentiation in MSI CRC affecting the expression of alternative exons encoding protein isoforms governing cell fate, while also targeting constitutive exons, making dMMR cells immunogenic in early stage before the onset of coding mutations. This signature is characterized by its similarity to the oncogenic U2AF1-S34F splicing mutation observed in several other non-MSI cancer. Conclusions Overall, these findings provide evidence that a very early RNA splicing signature partly driven by MSI impairs cell differentiation and promotes MSI CRC initiation, far before coding mutations which accumulate later during MSI tumorigenesis.

---

Fichiers liés : 13059_2024_Article_3340.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 05/08/2024
• Auteurs : Cyril GrandjeanChristophe VéronésiChristine RusterucciCharlotte GautierYannis MaillotMaïté LeschevinFrançoise FournetJan DrouaudPaulo MarceloLuciane ZabijakP DelavaultP SimierSophie BoutonKarine Pageau
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal Unité en Sciences Biologiques et Biotechnologies de Nantes BioEcoAgro BIOPI-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro BIOPI-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro - UMR transfrontalière INRAe - UMRT1158 BioEcoAgro BIOPI-UPJV BioEcoAgro - UMR transfrontalière INRAe - UMRT1158 BioEcoAgro BIOPI-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro BIOPI-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro - UMR transfrontalière INRAe - UMRT1158 Plateforme d’Ingénierie Cellulaire et Analyses des Protéines - UPJV Plateforme d’Ingénierie Cellulaire et Analyses des Protéines - UPJV Unité en Sciences Biologiques et Biotechnologies de Nantes Unité en Sciences Biologiques et Biotechnologies de Nantes BioEcoAgro BIOPI-UPJV BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment BioEcoAgro BIOPI-UPJV Université de Picardie Jules Verne BioEcoAgro - Equipe 1 - Functioning and adaptation of the plant in interaction with its environment
• Publié dans Plants le 27/10/2020

---

Résumé : Phelipanche ramosa is a root parasitic plant fully dependent on host plants for nutrition and development. Upon germination, the parasitic seedling develops inside the infected roots a specific organ, the haustorium, thanks to the cell wall-degrading enzymes of haustorial intrusive cells, and induces modifications in the host’s cell walls. The model plant Arabidopsis thaliana is susceptible to P. ramosa; thus, mutants in cell wall metabolism, particularly those involved in pectin remodeling, like Atpme3-1, are of interest in studying the involvement of cell wall-degrading enzymes in the establishment of plant–plant interactions. Host–parasite co-cultures in mini-rhizotron systems revealed that parasite attachments are twice as numerous and tubercle growth is quicker on Atpme3-1 roots than on WT roots. Compared to WT, the increased susceptibility in AtPME3-1 is associated with reduced PME activity in the roots and a lower degree of pectin methylesterification at the host–parasite interface, as detected immunohistochemically in infected roots. In addition, both WT and Atpme3-1 roots responded to infestation by modulating the expression of PAE- and PME-encoding genes, as well as related global enzyme activities in the roots before and after parasite attachment. However, these modulations differed between WT and Atpme3-1, which may contribute to different pectin remodeling in the roots and contrasting susceptibility to P. ramosa. With this integrative study, we aim to define a model of cell wall response to this specific biotic stress and indicate, for the first time, the role of PME3 in this parasitic plant–plant interaction.

---

Fichiers liés : plants-13-02168.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Gilles PernodAriel CohenPatrick MismettiOlivier SanchezIsabelle MahéYgal BenhamouAsmahane BenmazianeLaurent BertolettiVirginie BichonCoralie BozecAriel CohenFrancis CouturaudPhilippe DebourdeauPascale DielensegerÉric DouriezAntoine ÉliasOlivier EspitiaCorinne FrereYoann GaboreauPascale GendronPhilippe GirardOlivier HanonAhmed IdbaihSilvy LaporteDidier MayeurFarès MoustafaPierre-Marie RoyMarie-Eve Rougé BugatJeannot SchmidtFlorian ScottéMarie-Antoinette Pietri-Sevestre
• Organismes : F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne] CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Université Grenoble Alpes CHU Saint-Antoine [AP-HP] Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne] Service de Médecine vasculaire et thérapeutique [CHU de Saint-Etienne] F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne] Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis Hôpital Européen Georges Pompidou [APHP] Hôpital Louis Mourier - AP-HP [Colombes] Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis F-Crin INvestigation Network On Venous Thrombo-Embolism [CHU Saint-Etienne] Service de Médecine Interne [CHU Rouen] Hôpital Foch [Suresnes] Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] Hôpital Européen Georges Pompidou [APHP] Centre Hospitalier Régional Universitaire de Brest CHU Saint-Antoine [AP-HP] Centre Hospitalier Régional Universitaire de Brest Centre Hospitalier Joseph Imbert Institut Gustave Roussy Centre Hospitalier Intercommunal Toulon-La Seyne sur Mer - Hôpital Sainte-Musse Centre Hospitalier Universitaire de Nantes = Nantes University Hospital CHU Pitié-Salpêtrière [AP-HP] Université Grenoble Alpes Institut du Thorax Curie Montsouris [Paris] AP-HP - Hôpital Cochin Broca Hôtel Dieu [Paris] Institut du Cerveau = Paris Brain Institute Centre hospitalier Rene Pleven de Dinan Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] CHU Clermont-Ferrand CHU d'Angers [Département Urgences] Equipe EQUITY (CERPOP) Laboratoire de Psychologie Sociale et Cognitive CHU Clermont-Ferrand Département interdisciplinaire d’organisation des parcours patients CHU Amiens-Picardie
• Publié dans La Revue de Médecine Interne le 28/10/2020

---

Résumé : Le cancer est associé à un état d’hypercoagulabilité et constitue un facteur de risque indépendant bien connu de maladie thromboembolique veineuse, alors que l’association entre le cancer et la maladie thromboembolique artérielle est moins bien établie. La maladie thromboembolique artérielle, principalement définie comme un infarctus du myocarde ou un accident vasculaire cérébral, est significativement plus fréquente chez les patients atteints de cancer, indépendamment des autres facteurs de risque maladie vasculaire. Elle est associée à un risque de mortalité trois fois plus élevé. Les patients atteints d’un cancer du cerveau, du poumon, du pancréas ou colorectal ont le risque relatif le plus élevé de développer une maladie thromboembolique artérielle. Les traitements antithrombotiques doivent être utilisés avec prudence en raison du risque accru d’hémorragie.

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Ronny LauerwaldAna BastosMatthew J McgrathAna Maria Roxana PetrescuFrançois RitterRobbie M AndrewAntoine BerchetGrégoire BroquetDominik BrunnerFrederic ChevallierAlessandro CescattiSara FilipekAudrey Fortems‐cheineyGiovanni ForzieriPierre FriedlingsteinRichard FuchsChristoph GerbigSander HouwelingPiyu KeBas Jan Willem LerinkWanjing LiWei LiXiaojun LiIngrid T LuijkxGuillaume MonteilSaqr MunassarGert‐jan NabuursPrabir K. PatraP. PeylinJulia PongratzPierre RegnierMarielle SaunoisMart‐jan SchelhaasMarko ScholzeStephen SitchRona L ThompsonHanqin TianAki TsurutaChristopher WilsonJean‐pierre WigneronYitong YaoS. ZaehlePhilippe Ciais
• Organismes : Université Paris-Saclay Ecologie fonctionnelle et écotoxicologie des agroécosystèmes Max Planck Institute for Biogeochemistry Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Vrije Universiteit Amsterdam [Amsterdam] Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation INVerse pour les mesures atmosphériques et SATellitaires Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation INVerse pour les mesures atmosphériques et SATellitaires Interactions Sol Plante Atmosphère Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation des Surfaces et Interfaces Continentales Laboratoire des Sciences du Climat et de l'Environnement [Gif-sur-Yvette] Modélisation INVerse pour les mesures atmosphériques et SATellitaires Interactions Sol Plante Atmosphère
• Publié dans Global Biogeochemical Cycles le 25/10/2020

---

Résumé : In the framework of the RECCAP2 initiative, we present the greenhouse gas (GHG) and carbon (C) budget of Europe. For the decade of the 2010s, we present a bottom-up (BU) estimate of GHG netemissions of 3.9 Pg CO 2 -eq. yr 1 (using a global warming potential on a 100 years horizon), which are largely dominated by fossil fuel emissions. In this decade, terrestrial ecosystems acted as a net GHG sink of 0.9 Pg CO 2 -eq. yr 1 , dominated by a CO 2 sink that was partially counterbalanced by net emissions of CH 4 and N 2 O. For CH 4 and N 2 O, we find good agreement between BU and top-down (TD) estimates from atmospheric inversions. However, our BU land CO 2 sink is significantly higher than the TD estimates. We further show that decadal averages of GHG net-emissions have declined by 1.2 Pg CO 2 -eq. yr 1 since the 1990s, mainly due to a reduction in fossil fuel emissions. In addition, based on both data driven BU and TD estimates, we also find that the land CO 2 sink has weakened over the past two decades. A large part of the European CO 2 and C sinks is located in Northern Europe. At the same time, we find a decreasing trend in sink strength in Scandinavia, which can be attributed to an increase in forest management intensity. These are partly offset by increasing CO 2 sinks in parts of Eastern Europe and Northern Spain, attributed in part to land use change. Extensive regions of high CH 4 and N 2 O emissions are mainly attributed to agricultural activities and are found in Belgium, the Netherlands and the southern UK. We further analyzed interannual variability in the GHG budgets. The drought year of 2003 shows the highest net-emissions of CO 2 and of all GHGs combined.

---

Fichiers liés : Global Biogeochemical Cycles - 2024 - Lauerwald - Carbon and Greenhouse Gas Budgets of Europe Trends Interannual and.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Eugeni BeldaJacqueline CapeauJean-Daniel ZuckerEmmanuelle Le ChatelierNicolas PonsFlorian Plaza OñateBenoit QuinquisRohia AliliSoraya FellahiChristine KatlamaKarine ClémentBruno FèveStéphane JaureguiberryCécile GoujardOlivier LambotteJoël DoréEdi PriftiJean-Philippe Bastard
• Organismes : Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] Nutrition et obésités: approches systémiques (UMR-S 1269) Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] Nutrition et obésités: approches systémiques (UMR-S 1269) MetaGenoPolis MetaGenoPolis MetaGenoPolis MetaGenoPolis Nutrition et obésités: approches systémiques (UMR-S 1269) Lipodystrophies, adaptations métaboliques et hormonales, et vieillissement [CRSA] Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] CHU Tenon [AP-HP] Institut Pierre Louis d'Epidémiologie et de Santé Publique CHU Pitié-Salpêtrière [AP-HP] Nutrition et obésités: approches systémiques (UMR-S 1269) CHU Pitié-Salpêtrière [AP-HP] CHU Saint-Antoine [AP-HP] Centre de Recherche Saint-Antoine Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] AP-HP. Université Paris Saclay Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre de recherche en épidémiologie et santé des populations UFR Sciences de la santé Simone Veil Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes MetaGenoPolis MICrobiologie de l'ALImentation au Service de la Santé Unité de modélisation mathématique et informatique des systèmes complexes [Bondy] Nutrition et obésités: approches systémiques (UMR-S 1269) IMRB - SMCD/"Senescence, Metabolism and Cardiovascular Diseases" [Créteil] CHU Henri Mondor [Créteil] Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière]
• Publié dans BMC Medical Genomics le 23/10/2020

---

Résumé : Persons living with HIV (PWH) harbor an altered gut microbiome (higher abundance of Prevotella and lower abundance of Bacillota and Ruminococcus lineages) compared to non-infected individuals. Some of these alterations are linked to sexual preference and others to the HIV infection. The relationship between these lineages and metabolic alterations, often present in aging PWH, has been poorly investigated. In this study, we compared fecal metagenomes of 25 antiretroviral-treatment (ART)-controlled PWH to three independent control groups of 25 non-infected matched individuals by means of univariate analyses and machine learning methods. Moreover, we used two external datasets to validate predictive models of PWH classification. Next, we searched for associations between clinical and biological metabolic parameters with taxonomic and functional microbiome profiles. Finally, we compare the gut microbiome in 7 PWH after a 17-week ART switch to raltegravir/maraviroc. Three major enterotypes (Prevotella, Bacteroides and Ruminococcaceae) were present in all groups. The first Prevotella enterotype was enriched in PWH, with several of characteristic lineages associated with poor metabolic profiles (low HDL and adiponectin, high insulin resistance (HOMA-IR)). Conversely butyrate-producing lineages were markedly depleted in PWH independently of sexual preference and were associated with a better metabolic profile (higher HDL and adiponectin and lower HOMA-IR). Accordingly with the worst metabolic status of PWH, butyrate production and amino-acid degradation modules were associated with high HDL and adiponectin and low HOMA-IR. Random Forest models trained to classify PWH vs. control on taxonomic abundances displayed high generalization performance on two external holdout datasets (ROC AUC of 80-82%). Finally, no significant alterations in microbiome composition were observed after switching to raltegravir/maraviroc. High resolution metagenomic analyses revealed major differences in the gut microbiome of ART-controlled PWH when compared with three independent matched cohorts of controls. The observed marked insulin resistance could result both from enrichment in Prevotella lineages, and from the depletion in species producing butyrate and involved into amino-acid degradation, which depletion is linked with the HIV infection.

---

Fichiers liés : s12920-024-01978-5.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Hayet BaoucheCécile CouchoudHenri BoulangerSalima Ahriz-SaksiImene MansouriAbdelaziz HamaniPierre TaupinXavier FerreiraMarine PanayeJulien J. StirnemannOlivier MoranneJean-Philippe Jais
• Organismes : Service d'informatique médicale et biostatistiques [CHU Necker] Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Agence de la biomédecine [Saint-Denis la Plaine] Clinique de l'Estrée Clinique de l'Estrée Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Agence de la biomédecine [Saint-Denis la Plaine] Service d'informatique médicale et biostatistiques [CHU Necker] Service d'informatique médicale et biostatistiques [CHU Necker] Hôpital Edouard Herriot [CHU - HCL] Fédération pour la recherche en explorations et thérapeutiques innovantes in utéro Service de maternité [CHU Necker] Centre Hospitalier Universitaire de Nîmes Institut Desbrest d'Epidémiologie et de Santé Publique Service d'informatique médicale et biostatistiques [CHU Necker] Chronic Kidney Disease - Réseau Epidémiologie et Information en Néphrologie Fédération pour la recherche en explorations et thérapeutiques innovantes in utéro
• Publié dans Kidney International Reports le 26/10/2020

---

Résumé : Introduction: In women receiving chronic dialysis, fertility is impaired. The objectives of this study were to estimate the incidence rate of pregnancies among women of childbearing age (15–50 years) receiving chronic dialysis from 2006 to 2020 in France, to describe the pregnancy outcomes and renal management during pregnancy. Methods: This national observational, retrospective study was based on data from the French REIN registry matched with the National Health Data System. Results: Over the period 2006 to 2020 in France, 348 pregnancies were identified in 240 women receiving chronic dialysis. The overall incidence of pregnancy was 11.1, 95% confidence interval (CI) (9.9–12.3) cases per 1000 person-years. Hemodialysis was the predominant modality during pregnancy. Main maternal complications were preeclampsia (n = 19) and gestational diabetes (n = 11). The most obstetric complications were premature rupture of membranes (n = 14) and polyhydramnios (n = 5). These pregnancies resulted in 174 (50%) abortions (<22 weeks), including 104 elective abortions (29.9%), 44 miscarriages (12.6%), 17 therapeutic abortions (4.9%), 5 ectopic pregnancies (1.4%), and 4 hydatidiform moles (1.2%). The remaining 174 (50%) pregnancies with deliveries (≥22 weeks) resulted in 166 live births (70 full-term [42.2%], 96 preterm births [57.8%]), and 8 stillbirths. Median gestational age was 36 weeks (32–38) for 174 deliveries. Conclusion: There have been improvements in maternal and fetal outcomes regarding pregnancy on chronic dialysis. However, our study shows a significant proportion of elective abortions. Better fertility management of women receiving chronic dialysis is advised by contraception or by pregnancy planning and early multidisciplinary follow-up.

---

Fichiers liés : 1-s2.0-S2468024924017169-main.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Valentin GoutaudierRichard DangerRusan Ali CatarMaud RacapéAurélie PhilippeMichelle EliasMarc RaynaudOlivier AubertDidier BoutonFrançois GirardinÉric VicautSarhan YaicheJacques DemotesHarald HeideckeJean-Luc TaupinChristine Randoux-LebrunMohamad ZaidanEmmanuelle PapuchonHoa Le MaiThi van Ha NguyenFrancesc MoresoThierry BerneyJean VillardChristophe LegendreDuska DragunVassilios PapaloisLuciano PotenaMagali GiralPierre-Antoine GourraudSophie BrouardElena CrespoFabian HalleckKlemens BuddeOriol BestardAlexandre LoupyCarmen Lefaucheur
• Organismes : Paris-Centre de Recherche Cardiovasculaire Hôpital Necker - Enfants Malades [AP-HP] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Berlin Institute of Health Charité - UniversitätsMedizin = Berlin University Medicine Paris-Centre de Recherche Cardiovasculaire Laboratoire Universitaire de Biodiversité et Ecologie Microbienne Hopital Saint-Louis [AP-HP] Paris-Centre de Recherche Cardiovasculaire Paris-Centre de Recherche Cardiovasculaire Hôpital Necker - Enfants Malades [AP-HP] Assistance publique - Hôpitaux de Paris (AP-HP) Laboratoire Vibrations Acoustique centre Lyonnais d'Acoustique Hôpital Lariboisière-Fernand-Widal [APHP] Université Paris Cité Service d'Immunologie et d'Histocompatibilité Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris] Hôpital Bicêtre [AP-HP, Le Kremlin-Bicêtre] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Vall d'Hebron University Hospital [Barcelona] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Hôpitaux Universitaires de Genève = University Hospital of Geneva [Genève] Service de néphrologie adultes [CHU Necker] Charité - UniversitätsMedizin = Berlin University Medicine Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin Berlin Institute of Health Hammersmith Hospital NHS Imperial College Healthcare IRCCS Azienda Ospedaliero-Universitaria di Bologna Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Team 3 : Integrative transplantation, HLA, Immunology and genomics of kidney injury Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Centre de Recherche en Transplantation et Immunologie - Center for Research in Transplantation and Translational Immunology Team 4 : Deciphering organ immune regulation in inflammation and transplantation (DORI-t) Institut de Transplantation et de Recherche en Transplantation [CHU Nantes] Vall d'Hebron Research Institute - Institut de Recerca Vall d’Hebron Charité - UniversitätsMedizin = Berlin University Medicine Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin Berlin Institute of Health Charité - UniversitätsMedizin = Berlin University Medicine Humboldt-Universität zu Berlin = Humboldt University of Berlin = Université Humboldt de Berlin Berlin Institute of Health Vall d'Hebron University Hospital [Barcelona] Paris-Centre de Recherche Cardiovasculaire Service de néphrologie adultes [CHU Necker] Paris-Centre de Recherche Cardiovasculaire Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
• Publié dans Kidney International le 27/10/2020

---

Résumé : Non-invasive biomarkers are promising tools for improving kidney allograft rejection monitoring, but their clinical adoption requires more evidence in specifically designed studies. To address this unmet need, we designed the EU-TRAIN study, a large prospective multicentric unselected cohort funded by the European Commission. Here, we included consecutive adult patients who received a kidney allograft in nine European transplant centers between November 2018 and June 2020. We prospectively assessed gene expression levels of 19 blood messenger RNAs, four antibodies targeting non-human leukocyte antigen (HLA) endothelial antigens, together with circulating anti-HLA donor-specific antibodies (DSA). The primary outcome was allograft rejection (antibody-mediated, T cell-mediated, or mixed) in the first year post-transplantation. Overall, 412 patients were included, with 812 biopsies paired with a blood sample. CD4 gene expression was significantly associated with rejection, while circulating anti-HLA DSA had a significant association with allograft rejection and a strong association with antibody-mediated rejection. All other tested biomarkers, including AKR1C3, CD3E, CD40, CD8A, CD9, CTLA4, ENTPD1, FOXP3, GZMB, ID3, IL7R, MS4A1, MZB1, POU2AF1, POU2F1, TCL1A, TLR4, and TRIB1, as well as antibodies against angiotensin II type 1 receptor, endothelin 1 type A receptor, C3a and C5a receptors, did not show significant associations with allograft rejection. The blood messenger RNAs and non-HLA antibodies did not show an additional value beyond standard of care monitoring parameters and circulating anti-HLA DSA to predict allograft rejection in the first year post-transplantation. Thus, our results open avenues for specifically designed studies to demonstrate the clinical relevance and implementation of other candidate non-invasive biomarkers in kidney transplantation practice.

---

Fichiers liés : PIIS0085253824005659.pdf

---

Source

---

• Type de publi. : Article dans une revue
• Date de publi. : 01/08/2024
• Auteurs : Pierre-Régis BurgelIsabelle Sermet-GaudelusEmmanuelle GirodonIsabelle DurieuVéronique HoudouinCamille AudoussetJulie MaceyDominique GrenetMichele PorzioMarlène Murris-EspinPhilippe ReixMélisande BaravalleChantal BelleguicLaurent MelyJuliette VerhilleLaurence WeissMartine Reynaud-GaubertMarie MittaineRebecca HamidfarSophie RamelLaure CossonBenoit DouvryIsabelle Danner-BoucherPierre FoucaudCharlotte RoyEspérie BurnetCaroline RaynalMarie-Pierre AudrezetJennifer da SilvaClémence MartinReem KanaanNicolas CarlierIsabelle HonoréFrédérique ChedevergneElise DreanoAurélie HattonAlexandre HinzpeterIwona PrankeLaurence Le Clainche-VialaSophie MayerHarriet CorvolGuillaume ThouveninSandra de MirandaNatascha RemusBenoit DouvryLouise DuthoitThierry PerezOlivier Le RouzicNathalie WizlaClaire BonStéphanie BuiNora PoeyNathalie StremlerBérengère ColteyNadine DufeuJean LebihanAsma GabsiDelphine PouradierClaire AndréjakCinthia RamesMagali Dupuy-GrassetJeanne LanguepinChristophe MarguetStéphanie PramilBaptiste ArnouatAnnlyse FantonMichel AbelyBruno RavoninjatovoAurore BlondéAnne GuillaumotSebastien KiefferAurélie TatopoulosRaphaële Nove-JosserandCamille OhlmannThomas PerrinQuitterie ReynaudCatherine LlerenaSébastien QuétantSophie ValoisMarie-Laure DalphinBénédicte Richaud-ThiriezEric DeneuvilleRaphael ChironFloriane SocchiTiphaine BihouéeJulie MankikianThomas FlamentNathalie Coolen-AllouElsa GachelinCaroline PérissonConstance VuillardMarion DupuisWael AlkoussaSarah MarchalSylvie LeroyManuela ScalbertKarine CampbellMuriel LauransGuillaume LabbéSylvie MontcouquiolPascaline PriouPaola de CarliLydie LemonnierClémence DehillotteThierry Nouvel
• Organismes : Institut Cochin Institut Necker Enfants-Malades Université Paris Cité Hospices Civils de Lyon AP-HP Hôpital universitaire Robert-Debré [Paris] Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 Centre Hospitalier Universitaire de Bordeaux Hôpital Foch [Suresnes] Service de pneumologie [Hôpital Foch] Fédération de Médecine Translationnelle de Strasbourg Centre Hospitalier Universitaire [Strasbourg] Service Pneumologie-Allergologie [CHU Toulouse] Centre de Ressources et de Compétences en Mucoviscidose [CHU Toulouse] Hospices Civils de Lyon Hôpital Femme Mère Enfant [CHU - HCL] Centre National de la Recherche Scientifique Université Claude Bernard Lyon 1 Centre Hospitalier Universitaire [Rennes] Hôpital Renée Sabran [CHU - HCL] Service de Pneumologie et Immuno-Allergologie [CHU LIlle] Université Paris Cité Aix Marseille Université Centre Hospitalier Universitaire de Toulouse CHU de Grenoble-Alpes - Centre Hospitalier Universitaire CHU Grenoble Fondation ILDYS ITX-lab unité de recherche de l'institut du thorax UMR1087 UMR6291 Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] Centre Hospitalier Régional Universitaire [Montpellier] Génétique, génomique fonctionnelle et biotechnologies (UMR 1078)
• Publié dans The Lancet Respiratory Medicine le 23/10/2020

---

Résumé : Background: Elexacaftor-tezacaftor-ivacaftor has been approved in Europe for people with cystic fibrosis with at least one F508del CFTR variant. Additionally, it is approved by the US Food and Drug Administration (FDA) for people with cystic fibrosis with at least one of 177 rare variants. The aims of this study were to describe the clinical response to elexacaftor-tezacaftor-ivacaftor for people with cystic fibrosis without a F508del CFTR variant in France and to determine CFTR variant responsiveness to elexacaftor-tezacaftor-ivacaftor based on the observed clinical response. Methods: The French compassionate programme expanded access to elexacaftor-tezacaftor-ivacaftor to people with cystic fibrosis, aged 6 years and older, without a F508del variant, excluding those with two variants previously characterised as non-responsive. Participants at France's 47 cystic fibrosis centres were given a 4-6 week trial of elexacaftor-tezacaftor-ivacaftor and response was determined by a centralised committee based on evolution of clinical data, lung function, and sweat chloride concentration. Responsiveness of individual CFTR variants was derived from observed clinical responses. Findings: The first compassionnate programme was launched on May 19, 2022; by March 8, 2024, 516 people with cystic fibrosis had been identified for inclusion in this real-word study: 37 were not included due to the presence of two variants previously characterised as non-responsive to elexacaftor-tezacaftor-ivacaftor, and 479 (229 females [48%] and 250 males [52%]) received elexacaftor-tezacaftor-ivacaftor for 4-6 weeks. Among 443 participants who received no CFTR modulator before elexacaftor-tezacaftor-ivacaftor, 83 had at least one FDA-approved variant, of whom 81 (98%) were responders and continued elexacaftor-tezacaftor-ivacaftor; in responders, mean absolute change in sweat chloride was -44·5 mmol/L (95% CI -39·1 to -49·8) and percentage of predicted FEV1 (ppFEV1) was 11·1 percentage points (95% CI 8·4 to 13·7; both comparisons p<0·0001). Among 360 participants with no FDA-approved variant and no previous CFTR modulator, 177 (49%) were responders; in responders, mean absolute change in sweat chloride was -20·5 mmol/L (-17·2 to -23·8) and ppFEV1 was 13·2 percentage points (11·4 to 15·0; both comparisons p<0·0001). Among 36 participants who were receiving ivacaftor before elexacaftor-tezacaftor-ivacaftor, 32 (89%) continued elexacaftor-tezacaftor-ivacaftor. Of 251 individual CFTR variants, 64 (28 FDA-approved) were classified as responsive or possibly responsive to elexacaftor-tezacaftor-ivacaftor, and 123 (two FDA-approved) as non-responsive or possibly non-responsive to elexacaftor-tezacaftor-ivacaftor. Interpretation: In France, over half of the population with cystic fibrosis without a F508del variant responded to elexacaftor-tezacaftor-ivacaftor, with most responders having no FDA-approved variant. The treatment period was relatively short and further research is warranted to describe the long-term safety and effectiveness of elexacaftor-tezacaftor-ivacaftor in this population. Funding: Association Vaincre la Mucoviscidose, Société Française de la Mucoviscidose, and Filière Maladies Rares MUCO-CFTR.

---

Fichiers liés : 2024 Burgel et al., The expanded French.pdf

---

Source

---

• Type de publi. : Autre publication
• Date de publi. : 01/08/2024
• Auteurs : Ewen MullinsJean‐louis BressonTamas DalmayIan Crawford DewhurstMichelle EpsteinLeslie George FirbankPhilippe GuercheJan HejatkoHanspeter NaegeliFrancisco Javier MorenoFabien NoguéNils RostoksJose Juan Sánchez SerranoGiovanni SavoiniEve VeromannFabio VeronesiMichele ArdizzoneGiacomo de SanctisFederici SilviaAntonio Fernandez DumontAndrea GennaroJosé Ángel Gómez RuizPaschalina GrammatikouTilemachos GoumperisDafni Maria KagkliPaolo LenziAleksandra LewandowskaAna Martin CamargoFranco Maria NeriPietro PiffanelliTommaso RaffaelloKyriaki Xiftou
• Organismes : Institut Jean-Pierre Bourgin - Sciences du végétal
• Publié dans EFSA Journal le 01/11/2020

---

Résumé : Abstract Genetically modified maize MON 95275 was developed to confer protection to certain coleopteran species. These properties were achieved by introducing the mpp75Aa1.1, vpb4Da2 and DvSnf7 expression cassettes. The molecular characterisation data and bioinformatic analyses reveal similarity to known toxins, which was further assessed. None of the identified differences in the agronomic/phenotypic and compositional characteristics tested between maize MON 95275 and its conventional counterpart needs further assessment. The GMO Panel does not identify safety concerns regarding the toxicity and allergenicity of the Mpp75Aa1.1 and Vpb4Da2 proteins and the DvSnf7 dsRNA and derived siRNAs as expressed in maize MON 95275 and finds no evidence that the genetic modification would change the overall allergenicity of maize MON 95275. In the context of this application, the consumption of food and feed from maize MON 95275 does not represent a nutritional concern in humans and animals. The GMO Panel concludes that maize MON 95275 is as safe as the conventional counterpart and non‐GM maize varieties tested, and no post‐market monitoring of food/feed is considered necessary. In the case of accidental release of maize MON 95275 material into the environment, this would not raise environmental safety concerns. The post‐market environmental monitoring plan and reporting intervals are in line with the intended uses of maize MON 95275. The GMO Panel concludes that maize MON 95275 is as safe as its conventional counterpart and the tested non‐GM maize varieties with respect to potential effects on human and animal health and the environment.

---

Source